In one paragraphArticle in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Szilamér FerencziLaboratory of Molecular Neuroendocrinology, Institute of Experimental Medicine, Hungarian Research Network, H-1083 Budapest, Hungary.
Ildikó Bata-VidácsCentre of Research and Development, Eszterházy Károly Catholic University, H-3300 Eger, Hungary.ORCID 0000-0003-3019-8030 Judit KosztikCentre of Research and Development, Eszterházy Károly Catholic University, H-3300 Eger, Hungary.
István NagyCentre of Research and Development, Eszterházy Károly Catholic University, H-3300 Eger, Hungary.
Katalin InotaiAgro-Environmental Research Centre, Institute of Environmental Sciences, Hungarian University of Agriculture and Life Sciences, H-2100 Gödöllő, Hungary.
Olívia CsernusSection of Competent Authority for Biocides, Department for Chemical Safety and Competent Authorities, National Centre for Public Health and Pharmacy, H-1097 Budapest, Hungary.
Natália SzeőcsDepartment of Microbiology and Applied Biotechnology, Institute of Genetics and Biotechnology, Hungarian University of Agriculture and Life Sciences, H-2100 Gödöllő, Hungary.ORCID 0009-0009-9243-5602 Zsuzsanna SzőkeDepartment of Animal Biotechnology, Institute of Genetics and Biotechnology, Hungarian University of Agriculture and Life Sciences, H-2100 Gödöllő, Hungary.ORCID 0000-0001-9302-1115 Mónika VargaDepartment of Microbiology, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary.
András SzekeresDepartment of Microbiology, Faculty of Science and Informatics, University of Szeged, H-6726 Szeged, Hungary.ORCID 0000-0003-1651-4623 József KukolyaCentre of Research and Development, Eszterházy Károly Catholic University, H-3300 Eger, Hungary.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
Aflatoxin B1 (AFB1), a highly potent Group 1 human carcinogen produced by
Indexed as
Aflatoxin B1Aspergillus flavusSilageZea maysTemperatureAflatoxin B1aflatoxin B1aflRcypAgene expressionLimosilactobacillus fermentumomtAordAver1
Identifiers
PMID42347508
PMCPMC13307799
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390